IBD patients may ditch IV drips for simple shots
NCT ID NCT06381518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested switching 38 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) from intravenous infliximab to a subcutaneous (under-the-skin) injection. Researchers measured drug levels, quality of life, and patient satisfaction over 24 weeks. The goal was to see if the switch maintains effectiveness while being more convenient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab (CT-P13, a biosimilar) given as a subcutaneous injection
What this could lead to
If successful, this could show that switching to a subcutaneous injection is just as effective and more convenient for patients with inflammatory bowel disease.
What could go wrong
This is a small, single-center study with only 38 patients, so results may not apply to everyone. The switch might not work as well for some patients, and there is a risk of injection site reactions or loss of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zuyderland Medical Centre
Sittard, Netherlands